Jane Street Group LLC Cuts Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Jane Street Group LLC cut its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 5.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 332,126 shares of the biotechnology company’s stock after selling 18,776 shares during the period. Jane Street Group LLC owned about 0.22% of Heron Therapeutics worth $661,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in shares of Heron Therapeutics during the second quarter worth approximately $27,000. Cutter & CO Brokerage Inc. acquired a new stake in Heron Therapeutics during the 3rd quarter worth $39,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Heron Therapeutics during the second quarter worth $41,000. Sei Investments Co. acquired a new stake in shares of Heron Therapeutics in the second quarter valued at about $44,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Heron Therapeutics in the third quarter worth about $45,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HRTX. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 4th. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $1.66 on Friday. The company has a market capitalization of $252.48 million, a PE ratio of -9.22 and a beta of 1.60. The firm’s 50-day moving average is $1.51 and its two-hundred day moving average is $2.07. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the previous year, the firm posted ($0.17) EPS. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.